Cellectis (CLLS) Income from Continuing Operations (2015 - 2026)
Cellectis (CLLS) recorded quarterly Income from Continuing Operations of 8830000.0 in Q1 2026, up 91.83% quarter-over-quarter from 108074000.0 in Q4 2025, and down 473.36% on a YoY basis from 2365000.0 in Q1 2025.
Cellectis (CLLS) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Cellectis' Income from Continuing Operations history runs 12 years deep, the most recent figure standing at 8830000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 473.36% year-over-year to 8830000.0; the TTM figure through Mar 2026 stood at 62156000.0 (down 773.41% YoY), while the FY2025 annual figure was 67593000.0, down 83.87% from the prior year.
- Income from Continuing Operations was 8830000.0 for Q1 2026 at Cellectis, up from 108074000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 34366000.0 in Q3 2024 to a low of 108074000.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 11851235.29 across 5 years, with a median of 7595000.0 in 2023.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations plunged 3000.67% in 2023, then soared 479.75% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 2837000.0 in 2022, then slumped by 3000.67% to 87966000.0 in 2023, then surged by 35.95% to 56343000.0 in 2024, then slumped by 91.81% to 108074000.0 in 2025, then jumped by 91.83% to 8830000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 8830000.0 (Q1 2026), 108074000.0 (Q4 2025), and 33061000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | -8.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.83 Mn |
| Dec 31, 2025 | -108.07 Mn |
| Sep 30, 2025 | 33.06 Mn |
| Jun 30, 2025 | 21.69 Mn |
| Mar 31, 2025 | 2.37 Mn |
| Dec 31, 2024 | -56.34 Mn |
| Sep 30, 2024 | 34.37 Mn |
| Jun 30, 2024 | 28.84 Mn |
| Mar 31, 2024 | 11.65 Mn |
| Dec 31, 2023 | -87.97 Mn |
| Sep 30, 2023 | -14.24 Mn |
| Jun 30, 2023 | -7.60 Mn |
| Mar 31, 2023 | -17.48 Mn |
| Dec 31, 2022 | -2.84 Mn |
| Sep 30, 2022 | -11.11 Mn |
| Jun 30, 2022 | -13.36 Mn |
| Mar 31, 2022 | -5.62 Mn |
| Dec 31, 2021 | -7.06 Mn |
| Sep 30, 2021 | -42.37 Mn |
| Jun 30, 2021 | -37.48 Mn |